Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 16;481(5):685–694. doi: 10.1007/s00428-022-03378-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Comparison of HercepTest (mAb) (HcT) and PATHWAY 4B5 (4B5) with respect to IHC scores and FISH status. A According to ASCO/CAP IHC scoring, all ISH positive cases (filled symbols) were scored IHC 3 + or IHC 2 + by using HcT. In two of the ISH positive tumors, 4B5 was IHC 1 + (red circle). B Detailed analysis of 53 tumors scored as IHC 0 according to ASCO/CAP by 4B5 (see cases within blue frames in A) with 41 tumors showing no staining and 12 cases with HER2 expression in < 10% of cells (grey area). Using HcT, 16 cases were shifted up to IHC score 1 + and in 3 cases to IHC 2 + (matching to HER2-low category). Fourteen cases were shifted from no staining by 4B5 to some staining (< 10%, grey zone) by HcT (matching to HER2 ultra-low category: 0 < 1 +). IHC scores were unchanged in 20 cases (19 IHC 0, 1 IHC 0 < 1 +)